



## URINARY EXOSOMAL BIOMARKERS FOLLOW-UP IN THYROID CANCER PATIENTS WITH ABLATIVE THERAPY

**PI :** Prof. Chih-Yuan Wang  
 Department of Internal Medicine,  
 National Taiwan University Hospital.

### Experience:

1995-1998: Secretary General, The Endocrinology  
 Society of the Republic of China

2005-present: Education Committee, The Society of  
 Ultrasound in Medicine, Taiwan

2007-present: Board of Directors, Endocrine Society, Taiwan

2008-present: Editor, Journal of Medical Ultrasound (West Pacific)

2010-present: Board of Directors, Taiwan Association of Diabetic Educator, Taiwan

2012-present: Executive editor, Journal of Internal Medicine of Taiwan, Taiwan

### Market Needs:

Follow-up in thyroid cancer patients with Ablative Therapy

### Our Technology:

We use peptide sequence to quantify the levels of thyroglobulin in urine exosome. Significant reduction in cost-spending in rhTSH consumption, and patients do not need to stop using thyroid hormone during the course of cancer follow-up. We also use galectin-3 as a comparator to confirm the trends of thyroglobulin levels. Galectin-3 could act to be the modulator of cell growth via galactoside-binding protein, correlating to occurrence and metastasis of papillary thyroid carcinoma.

### Strength:

Our technique provides a non-invasive, reproducible, convenient, serial and correct follow-up for patients with thyroid cancer.

### Competing Products:

### Intellectual Properties:

This technology may be patented.

### Contact (do not need to fill out):

Center for Industry-Academia Cooperation, NTU  
 Tel: 02-3366-9945, E-mail: ntuciac@ntu.edu.tw

